Fortis Healthcare Ltd
FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. [1]
Company controls its diagnostics business through its 57% owned subsidiary SRL Limited. It is amongst the largest private diagnostics chains. It has a presence in over 600 cities and towns, with an established strength of 415 laboratories, 8,200 direct clients and 1,400 Collection Centers. [2]
- Market Cap ₹ 59,264 Cr.
- Current Price ₹ 785
- High / Low ₹ 1,105 / 745
- Stock P/E 55.6
- Book Value ₹ 131
- Dividend Yield 0.13 %
- ROCE 13.4 %
- ROE 11.2 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 64.3% CAGR over last 5 years
Cons
- Stock is trading at 5.99 times its book value
- Company has a low return on equity of 9.87% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3,966 | 4,199 | 4,574 | 4,561 | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 9,128 | 9,506 | |
| 3,857 | 4,106 | 4,220 | 4,287 | 4,238 | 4,022 | 3,626 | 4,649 | 5,196 | 5,625 | 6,195 | 7,043 | 7,375 | |
| Operating Profit | 109 | 92 | 354 | 274 | 231 | 610 | 404 | 1,069 | 1,101 | 1,268 | 1,588 | 2,085 | 2,131 |
| OPM % | 2.8% | 2.2% | 8% | 6% | 5% | 13% | 10% | 19% | 17% | 18% | 20% | 23% | 22% |
| 92 | 299 | 649 | -689 | 228 | 126 | 95 | 367 | 157 | 64 | -11 | 45 | 42 | |
| Interest | 152 | 133 | 229 | 258 | 337 | 205 | 166 | 147 | 129 | 131 | 184 | 314 | 325 |
| Depreciation | 235 | 225 | 222 | 239 | 233 | 292 | 291 | 301 | 316 | 342 | 386 | 449 | 470 |
| Profit before tax | -185 | 34 | 552 | -912 | -110 | 239 | 43 | 988 | 814 | 858 | 1,007 | 1,366 | 1,378 |
| Tax % | 2% | -24% | 13% | 2% | 103% | 62% | 230% | 20% | 22% | 25% | 20% | 22% | |
| -130 | 42 | 479 | -934 | -224 | 91 | -56 | 790 | 633 | 645 | 809 | 1,064 | 1,070 | |
| EPS in Rs | -3.10 | 0.40 | 8.14 | -19.46 | -3.96 | 0.77 | -1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.80 | 13.88 |
| Dividend Payout % | -1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 10% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 18% |
| 3 Years: | 13% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 60% |
| 5 Years: | 64% |
| 3 Years: | 27% |
| TTM: | 16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 24% |
| 3 Years: | 32% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 3,585 | 3,998 | 4,626 | 3,543 | 5,846 | 5,906 | 5,365 | 5,423 | 6,487 | 6,908 | 8,162 | 9,141 |
| 1,784 | 1,513 | 2,217 | 1,962 | 2,010 | 1,594 | 1,531 | 1,255 | 926 | 1,155 | 2,475 | 3,473 | |
| 1,760 | 1,257 | 2,227 | 2,455 | 2,875 | 2,781 | 3,216 | 4,082 | 3,921 | 4,153 | 1,985 | 2,465 | |
| Total Liabilities | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,833 |
| 4,218 | 3,642 | 5,419 | 4,992 | 8,477 | 8,802 | 8,799 | 9,416 | 9,426 | 9,874 | 10,424 | 12,230 | |
| CWIP | 228 | 226 | 268 | 226 | 450 | 204 | 165 | 193 | 228 | 542 | 407 | 434 |
| Investments | 1,464 | 1,452 | 1,878 | 1,732 | 270 | 175 | 186 | 104 | 210 | 230 | 169 | 243 |
| 1,682 | 1,913 | 2,023 | 1,529 | 2,290 | 1,856 | 1,716 | 1,803 | 2,225 | 2,326 | 2,378 | 2,926 | |
| Total Assets | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,833 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 | 195 | 966 | 493 | -179 | 172 | 485 | 865 | 822 | 1,100 | 1,424 | 1,601 | |
| 213 | 122 | -1,001 | -333 | -3,279 | 63 | -131 | -501 | -372 | -889 | -780 | -1,537 | |
| -304 | -354 | 259 | -672 | 4,257 | -862 | -143 | -517 | -471 | -86 | -714 | 164 | |
| Net Cash Flow | -66 | -37 | 225 | -513 | 799 | -627 | 212 | -153 | -21 | 125 | -70 | 228 |
| Free Cash Flow | -181 | -162 | 689 | 437 | -261 | 35 | 274 | 750 | 367 | 172 | 591 | 673 |
| CFO/OP | 131% | 354% | 304% | 187% | 30% | 84% | 108% | 101% | 100% | 104% | 97% | 90% |
Ratios
Consolidated / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 38 | 39 | 38 | 38 | 44 | 36 | 41 | 33 | 34 | 33 | 37 | 42 |
| Inventory Days | 25 | 23 | 23 | 24 | 22 | 30 | 29 | 33 | 31 | 24 | 23 | 24 |
| Days Payable | 207 | 218 | 215 | 279 | 296 | 226 | 205 | 178 | 179 | 164 | 161 | 165 |
| Cash Conversion Cycle | -144 | -156 | -155 | -217 | -230 | -161 | -135 | -112 | -115 | -107 | -101 | -99 |
| Working Capital Days | -71 | -69 | -87 | -113 | -234 | -150 | -56 | -35 | -22 | -124 | -30 | -34 |
| ROCE % | -0% | 3% | 11% | 3% | 6% | 4% | 2% | 10% | 10% | 10% | 12% | 13% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Diagnostic Tests Volume (Agilus) Mn tests |
|
||||
| International Patient Revenue Share (Hospital Business) % |
|||||
| ALOS (Average Length of Stay) Days |
|||||
| ARPOB (Average Revenue Per Occupied Bed) INR Cr p.a. |
|||||
| Customer Touchpoints (CTPs) - Agilus Diagnostics Count |
|||||
| Healthcare Facilities (Hospitals) Count |
|||||
| Hospital Occupancy % |
|||||
| Operational Beds (Hospitals, incl. O&M) Beds |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement / Press Release Filed By IHH Healthcare Berhad ('IHH')
- IHH says Supreme Court disposed Fortis SLP on Sept. 25; plans 51% stake and 10,000 beds by 2031.
-
Update On Special Leave Petition (''SLP'') Filed By The Company Before The Hon''ble Supreme Court Of India
- Supreme Court allows forensic audit in Daiichi Sankyo-Fortis dispute; no liability, penalty or fine.
-
Closure of Trading Window
- Trading window closed from October 1, 2026 until 48 hours after Q2 FY27 results.
-
Update On Material Litigation Filed By Northern TK Venture Pte Ltd. (''NTK''), The Promoter Shareholder Of The Company, Against Daiichi Sankyo Company, Limited Before The Tokyo District Court In Japan
- NTK appealed Tokyo District Court judgment to Tokyo High Court on 24 September 2026.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Fortis signed 29-year agreements for a 400+ bed Delhi hospital and a ₹567 crore loan.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from nse
-
Annual Report 2013
from bse
Concalls
-
Sep 2026Transcript REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT REC
-
Jan 2026PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024PPT
-
May 2024PPT
-
Feb 2024Transcript
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Nov 2023PPT
-
Aug 2023Transcript PPT
-
Aug 2023PPT
-
May 2023Transcript PPT
-
May 2023PPT
-
Feb 2023Transcript
-
Nov 2022Transcript
-
Aug 2022Transcript
-
May 2022Transcript
-
May 2022Transcript
-
Aug 2021PPT
-
May 2021PPT
-
Jun 2020PPT
-
Feb 2020PPT
-
Jun 2019Transcript
-
Feb 2019PPT
-
Jul 2018Transcript
-
Jun 2018PPT
-
Mar 2018PPT
-
Aug 2017PPT
-
May 2017PPT
-
Feb 2017PPT
-
Aug 2016PPT
-
May 2016PPT
-
Feb 2016PPT
Business Segments:[1]
a) Hospital Segment:
Co. operates multi-specialty and super-specialty hospitals providing inpatient and outpatient treatments across various disciplines.
-Network:[2]
The company has a highly accredited health
care network in India with 8100+ doctors, 9500+ nurses, and 28,500+ employees.
It operates 36 hospitals, including joint
ventures and O&M centers, with 5,800 operational beds. The network includes
4 JCI-accredited and 34 NABH-accredited facilities.